PluroGen Therapeutics, Inc.
503 Broadleaf Way
Charlottesville, VA 22911
Tel: 443 994 0101
Fax: 410 990 9817
www.plurogen.com
503 Broadleaf Way
Charlottesville, VA 22911
Tel: 443 994 0101
Fax: 410 990 9817
www.plurogen.com
| News Release |
FOR IMMEDIATE RELEASE Contact: Neal G. Koller
President & CEO
27 October 2007 Board of Directors
University of Virginia Patent
Foundation Licenses Silver Nanoparticle Technology to U.Va. Start-Up PluroGen Therapeutics Inc.
443 994 0101
PLUROGEN THERAPEUTICS INC. PRESENTS AT THE
LIFE SCIENCES VENTURE SUMMIT
IN NEW YORK CITY
(Charlottesville, VA, October 23, 2007) – PluroGen Therapeutics, Inc. today announced it presented at the Life
Sciences Venture Summit in New York City.
Neal G. Koller, President & CEO of PluroGen, made the presentation to an audience of venture capitalists. Mr.
Koller commented on the presentation “PluroGen had a wonderful opportunity to present the significant progress
our company has made to a key group of potential investors. This conference is held once per year with only 46
companies asked to present. It is quite an honor to have been selected.”
About PluroGen Therapeutics, Inc.
Headquartered in Charlottesville, Va., PluroGen is a wound healing company commercializing its patent-protected
gel technology platform that provides superior and differentiated physical and bio-active benefits to wound
healing. The platform delivers drug and non-drug compounds as protected and advanced therapeutic products
for simple and complex wound healing. PluroGen’s product pipeline targets improved, protected therapies for the
6 Areas of Therapeutic Treatment of tissue healing (cleansing, infection, pain, inflammation, tissue salvage, tissue
regeneration).
The company’s first two products, PluroGel™ Silver Sulfadiazine and PluroGel™ TAG, are topical antimicrobial
products. Currently in routine use, PluroGel™ TAG is showing superior results at the University of Virginia Medical
Center on more than 2,000 patients, both chronic wound and burn. PluroGen’s management team, operational
partners, Boards and Principal Investigators are recognized global clinical and commercial leaders in PluroGen’s
target markets of wound care and burn care and in the life sciences industry.
For more information about PluroGen Therapeutics, Inc., visit the Company’s web site at www.plurogen.com
About the Life Sciences Venture Summit
The 2007 Life Sciences & Healthcare Venture Summit is the premier bioscience industry gathering, connecting
senior executives of early stage biotech, pharmaceutical, healthcare, medical device and diagnostic companies
with venture capitalists, angel investors, corporate VCs and professional service firms. This premier forum for the
emerging growth bioscience industry featured 25+ Venture Capital Speakers: Interactive VC Panels, 40 of the
hottest emerging companies seeking funding, Emerging Company Presentations and High-level networking.
Statements included in this press release that are not historical in nature are "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that forward-looking
statements are subject to certain risks and uncertainties, which could cause actual results to differ materially and
which are identified from time to time in the Company’s reports filed with the U.S. Securities and Exchange
Commission. PluroGen Therapeutics, Inc. claims the protection of the Safe Harbor for forward-looking statements
contained in the Private Securities Litigation Reform Act of 1995.
Information included on PluroGen Therapeutics, Inc website is not incorporated herein by reference or otherwise.
President & CEO
27 October 2007 Board of Directors
University of Virginia Patent
Foundation Licenses Silver Nanoparticle Technology to U.Va. Start-Up PluroGen Therapeutics Inc.
443 994 0101
PLUROGEN THERAPEUTICS INC. PRESENTS AT THE
LIFE SCIENCES VENTURE SUMMIT
IN NEW YORK CITY
(Charlottesville, VA, October 23, 2007) – PluroGen Therapeutics, Inc. today announced it presented at the Life
Sciences Venture Summit in New York City.
Neal G. Koller, President & CEO of PluroGen, made the presentation to an audience of venture capitalists. Mr.
Koller commented on the presentation “PluroGen had a wonderful opportunity to present the significant progress
our company has made to a key group of potential investors. This conference is held once per year with only 46
companies asked to present. It is quite an honor to have been selected.”
About PluroGen Therapeutics, Inc.
Headquartered in Charlottesville, Va., PluroGen is a wound healing company commercializing its patent-protected
gel technology platform that provides superior and differentiated physical and bio-active benefits to wound
healing. The platform delivers drug and non-drug compounds as protected and advanced therapeutic products
for simple and complex wound healing. PluroGen’s product pipeline targets improved, protected therapies for the
6 Areas of Therapeutic Treatment of tissue healing (cleansing, infection, pain, inflammation, tissue salvage, tissue
regeneration).
The company’s first two products, PluroGel™ Silver Sulfadiazine and PluroGel™ TAG, are topical antimicrobial
products. Currently in routine use, PluroGel™ TAG is showing superior results at the University of Virginia Medical
Center on more than 2,000 patients, both chronic wound and burn. PluroGen’s management team, operational
partners, Boards and Principal Investigators are recognized global clinical and commercial leaders in PluroGen’s
target markets of wound care and burn care and in the life sciences industry.
For more information about PluroGen Therapeutics, Inc., visit the Company’s web site at www.plurogen.com
About the Life Sciences Venture Summit
The 2007 Life Sciences & Healthcare Venture Summit is the premier bioscience industry gathering, connecting
senior executives of early stage biotech, pharmaceutical, healthcare, medical device and diagnostic companies
with venture capitalists, angel investors, corporate VCs and professional service firms. This premier forum for the
emerging growth bioscience industry featured 25+ Venture Capital Speakers: Interactive VC Panels, 40 of the
hottest emerging companies seeking funding, Emerging Company Presentations and High-level networking.
Statements included in this press release that are not historical in nature are "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that forward-looking
statements are subject to certain risks and uncertainties, which could cause actual results to differ materially and
which are identified from time to time in the Company’s reports filed with the U.S. Securities and Exchange
Commission. PluroGen Therapeutics, Inc. claims the protection of the Safe Harbor for forward-looking statements
contained in the Private Securities Litigation Reform Act of 1995.
Information included on PluroGen Therapeutics, Inc website is not incorporated herein by reference or otherwise.